Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

irradiated allogeneic human lung cancer cells expressing OX40L-Ig vaccine HS-130

An allogeneic irradiated human lung cancer cell vaccine expressing a fusion protein composed of the OX40 ligand (OX40L) linked to an immunoglobulin (Ig) (OX40L-Ig), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of irradiated allogeneic human lung cancer cells expressing OX40L-Ig vaccine HS-130, the irradiated lung cancer cells continuously express OX40L-Ig. OX40L may then target, bind to and activate its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40; CD134), which is expressed on activated T cells. OX40L/OX40 binding promotes increased cytokine production, and induces the proliferation and activation of memory and effector T lymphocytes against the human lung cancer cells. In turn, this promotes a CTL-mediated immune response against the endogenous lung cancer cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:HS 130
HS-130
HS130
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search